NCT06417008View on ClinicalTrials.gov

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

1,080

Participants

Timeline

Start Date

May 28, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2030

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG

HS-20117

Participants will receive HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)

DRUG

Aumolertinib

110 mg orally once daily.

Trial Locations (2)

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310000

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Hansoh BioMedical R&D Company

INDUSTRY

NCT06417008 - A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter